The introduction of immune checkpoint inhibitors in cancer treatment highlights the negative regulation of anti-tumor immunity, such as effector T-cell exhaustion in the tumor microenvironment. However, the mechanisms underlying the induction and prevention of T-cell exhaustion remain largely unknown. We found that CD69, a type II glycoprotein known to regulate inflammation through T-cell migration and retention in tissues, plays an important role in inducing the exhaustion of tumorinfiltrating T cells. Cd69 -/-mice showed reduced tumor growth and metastasis in a 4T1-luc2 murine breast cancer model, in which increased numbers of tumor-infiltrating lymphocytes, relatively little T-cell exhaustion, and enhanced IFNγ production were observed. Anti-CD69 monoclonal antibody treatment attenuated the T-cell exhaustion and tumor progression in tumor-bearing mice. These findings highlight a novel role of CD69 in controlling the tumor immune escape mediated by T-cell exhaustion and indicate that CD69 is a novel target for cancer immunotherapy.
Introduction
CD69, a type II transmembrane glycoprotein with a C-type lectin domain, is known to be a marker of early leukocyte activation (1, 2) . CD69 is also known to be expressed on tissueresident memory T (T RM ) cells and to play an important role in the residency of these cells within various tissues (3) (4) (5) (6) (7) (8) (9) . Furthermore, recent studies have shown that the expression of CD69 on activated T cells is required for the recruitment and maintenance of these T cells in inflamed tissues, establishing and exacerbating tissue inflammation (2, (10) (11) (12) (13) . These data suggest that within various tissues, CD69 plays a crucial role in the retention of the cells on which it is expressed. One well-known mechanism underlying the cell retention mediated by CD69 is S1P 1 -dependent (14) , in which CD69 inhibits the surface expression of S1P 1 via direct interaction and prevents the egress of CD69-expressing cells from the thymus and lymph nodes (LNs) (15, 16) . Recent studies have shown that the CD69 ligands, myosin light chain 9 and 12 (Myl9/12), which are expressed in inflamed tissues, are used to recruit CD69-expressing activated T cells into inflamed tissues for their retention (13) .
The involvement of CD69 in tumor progression has been examined using Cd69 -/-mice and anti-CD69 antibody treatment (17) (18) (19) . The involvement of NK cell-mediated anti-tumor responses (17, 19) and dendritic cell-based anti-tumor effects (18) were suggested. However, the cellular and molecular mechanisms, including the role of CD69 + T cells in anti-tumor immunity and the reason why CD69 deficiency results in enhanced anti-tumor responses, remain unclear. Tumor progression is known to be associated with the exhaustion of tumor-infiltrating T lymphocytes (20) ; however, little is known about how T-cell exhaustion can be prevented in tumors, prompting us to wonder whether the expression of CD69 might be involved in the anti-tumor immune activity of tumor-infiltrating lymphocytes (TILs).
In this study, we examined the roles of CD69 in anti-tumor immunity. We found that the growth and metastasis of murine 4T1-luc2 breast cancer tumors were significantly attenuated in Cd69 -/-mice and that the attenuation of tumor progression was associated with the increase in tumor-infiltrating T cells and reduced CD8 T-cell exhaustion. We also showed that anti-CD69 antibody treatment resulted in enhanced antitumor activity, indicating that CD69 is a novel target for cancer immunotherapy.
Methods

Mice
C57BL/6, BALB/c and BALB/c-nu/nu mice were purchased from CLEA Co. (Tokyo, Japan). CD69-deficient mice were established in our laboratory (12) and backcrossed into both C57BL/6 and BALB/c mice >15 times. All mice were maintained under specific pathogen-free conditions and used at 6-16 weeks of age. All animal experiments were approved by the Chiba University Review Board for Animal Care.
Cell culture
The murine mammal cancer cell line containing the firefly luciferase gene (4T1-luc2) was kindly provided by Dr Y. Hayakawa (Toyama University). 4T1-luc2, CT26 and B-cell lymphoma (A20) cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Serum Source International).
Tumor growth in vivo
4T1-luc2 breast cancer was induced as previously described (21) . In brief, 5 × 10 4 4T1-luc2 cells were inoculated into the mammary fat pad on day 0. Tumor growth and lung metastasis were analyzed at the indicated time points. Tumor growth and lung metastasis were measured based on the tumor luciferase activity. In brief, VivoGlo Luciferin (100 mg kg −1 ; Promega) was intra-peritoneally injected 15 min before tumor or lung resection. After the isolation of the tumor and lung tissue, the tissues were placed into VivoGlo Luciferin (1 mg ml −1 ), and the luminescence was measured using the IVIS Lumina II In Vivo Imaging System (Caliper Life Sciences). As indicated, monoclonal anti-CD69 (clone: H1.2F3, Immuno-Biological Laboratories) or isotype control antibodies (100 µg) were intra-peritoneally injected twice a week for 5 weeks. CT26 colon cancer (2 × 10 6 ) and A20 B-cell lymphoma (2 × 10 6 ) cell lines were inoculated subcutaneously and monitored as previously described (22) .
Mixed bone marrow chimeras
Mixed bone marrow (BM) chimeras were generated by transplanting an equal number of BM cells (8 × 10 6 each) from Cd69 +/+ CD90.1 and Cd69 −/− CD90.2 BALB/c mice into lethally irradiated (9.5 Gy/2 Fr) Cd69 +/+ CD90.1 or CD90.1/ CD90.2 mice. Chimeric mice were used as the host mice for tumor transplantation, at 6 weeks after reconstitution.
Adoptive T-cell transfer to BALB/c nu/nu mice
Lymphocytes of Cd69
+/+ and Cd69 −/− BALB/c mice were collected from the cervical, mesentery, axillary and inguinal LNs, and CD49b
-CD45R -cells (>95% T cells) were negatively sorted using an Auto MACS system (Miltenyi Biotec) according to the manufacturer's protocol. An equal mixture of purified T cells (4 × 10 7 ) from Cd69 +/+ mice or Cd69 -/-mice were injected into BALB/c nu/nu mice the day before 4T1 inoculation, as stated above.
Isolation of mononuclear cells from tumor tissues
Tumor tissues were minced into small pieces and dissociated using a Tumor Dissociation Kit (Miltenyi Biotec) and Gentle MACS Dissociator™ (Miltenyi Biotec) according to the manufacturer's protocol. Dissociated cells were filtered through a 70-µm mesh and separated by Ficoll centrifugation to obtain lymphocytes.
Flow cytometry
TILs were stained with fluorochrome-conjugated monoclonal antibodies against CD3ε (145-2C11), CD4 (RM4-5), CD8α (53-6.7), CD69 (H1.2F3), TCRγδ (GL3), CD25 (PC61), Tim3 (RMT3-23), CD19 (1D3), CD49b (HMa2), CD1d-PBS57 PE and PD-1 (29F.1A12), fixed and permeabilized with an Intracellular Fixation & Permeabilization Buffer Set (eBioscience), and stained with an antibody against Foxp3 (FJK-16s).
To detect IFNγ-and TNFα-producing cells, TILs were collected from the mice 4 weeks after 4T1-luc2 inoculation and stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin in monensin-containing medium for 4 h. After cell surface staining, the cells were treated with a Fixation/ Permeabilization solution kit (BD Biosciences) according to the manufacturer's protocol and stained with fluorochromeconjugated monoclonal antibodies against IFNγ (XMG1.2) and TNFα (MP-XC22).
The conjugated monoclonal antibodies were obtained from BD, eBioscience, Tonbo or BioLegend. Data were acquired on a Canto II flow cytometer (BD) and analyzed using the FlowJo software program.
Statistical analyses
All experiments were performed independently at least three times. The results of the statistical analyses are expressed as the mean ± SE of the mean, unless otherwise indicated. Intergroup variance was assessed using the F-test. For normally distributed data, statistical significance was determined using a paired or unpaired two-sided Student's t-test; an unpaired two-sided Welch's t-test was used to analyze groups that showed differing variance. P values of <0.05 were considered statistically significant.
Results
Tumor progression was attenuated in CD69-deficient mice
To investigate the roles of the CD69 molecule in anti-tumor immunity, we first examined the tumor progression in Cd69
and Cd69 -/-mice. We utilized the 4T1-luc2 murine mammary carcinoma cell line, which contains the firefly luciferase gene, allowing the tumor growth to be quantified based on the luciferase activities detected by an IVIS (21) . 4T1-luc2 tumor cells were inoculated into the mammary fat pad of BALB/c female mice, and tumor progression was examined 3 and 5 weeks later (Supplementary Figure S1A) . The 4T1-luc2 tumor continuously grew in Cd69 +/+ mice until 5 weeks, while the tumor growth was significantly inhibited in Cd69 -/-mice (Fig. 1A ). Since it has been reported that the injection of 4T1-luc2 tumor cells into the mammary fat pad promotes spontaneous metastasis, most frequently in the lungs (23), we next examined the extent of lung metastasis in Cd69 +/+ and Cd69 -/-mice. We found that lung metastasis was significantly attenuated (to 5%) in Cd69 -/-mice at 5 weeks after tumor inoculation (Fig. 1B) . Furthermore, the growth of the A20 diffuse large B-cell lymphoma (Supplementary Figure S1B) and CT26 colon cancer cell lines (Supplementary Figure S1C) in Cd69 -/-mice was significantly decreased in comparison to Cd69 +/+ mice. These data indicate that tumor progression was significantly attenuated in Cd69 -/-mice.
The number of tumor-infiltrating T lymphocytes was increased in Cd69 -/-mice
To explore the mechanisms underlying the attenuation of tumor progression in Cd69 -/-mice, we next examined the possibility that the anti-tumor immune responses were enhanced in Cd69 -/-mice, thereby preventing tumor progression. We first simply examined the number of TILs at 2, 3 and 5 weeks after 4T1-luc2 tumor inoculation and found that Cd69 -/-mice had more TILs, especially CD4 + and CD8 + T cells, at all of the examined time points (Fig. 2A) . In contrast, the numbers of NK cells (TCRβ -/-mice was higher than that in the Cd69 +/+ mice, but only at the latest time point (5 weeks) ( Fig. 2A) . In addition, the absolute number of CD4 + Foxp3 + regulatory T (T reg ) cells at 3 weeks after tumor inoculation in Cd69 -/-mice was higher than that in Cd69 +/+ mice; however, this increase was due to the increased number of total CD4 + T cells, since the frequency of T regs in CD4 + T cells in Cd69 -/-mice was significantly lower than that in Cd69 +/+ mice at 2-3 weeks after tumor inoculation (Supplementary Figure S2) . Notably, the percentage of tumorinfiltrating CD4 + and CD8 + T cells that expressed CD69 was significantly increased as time passed after tumor inoculation (Fig. 2B) , suggesting that CD69 molecules on tumor-infiltrating T cells play a role in the anti-tumor effects.
We next examined whether or not a loss of CD69 expression on T cells was responsible for the increased number of TILs and attenuated tumor progression. We established mixed BM chimeric mice in which equal numbers of BM cells from Cd69 +/+ CD90.1 and Cd69 -/-CD90.2 mice were injected into lethally irradiated Cd69 +/+ CD90.1 host mice; 6 weeks later, the reconstituted mice were inoculated with 4T1-luc2 tumor cells (Fig. 2C) . We analyzed the cell number ratio of CD90.2 CD69-deficient cells to CD90.1 CD69-sufficient cells in the TILs, which was normalized by the cell number ratio of these cells in the spleen. We found that the CD90.2 CD69-deficient CD4 + and CD8 + T cells were infiltrating into the tumor 1.5 times more efficiently than the CD90.1 CD69-sufficient CD4 + and CD8 + T cells (Fig. 2D ). These data demonstrate that the expression of CD69 on T cells negatively regulates the number of tumor-infiltrating T cells.
The anti-tumor cytokine production by TILs was enhanced in Cd69
-/-mice
To examine whether or not the anti-tumor effector functions of TILs were indeed enhanced in Cd69 -/-mice, TILs were prepared from the mice at 4 weeks after 4T1-luc2 inoculation and Figure S3B) . Notably, the frequencies of IFNγ-producing and IFNγ/TNFα-double-producing cells among CD8 + T cells in Cd69 -/-mice were significantly higher than those in Cd69 +/+ mice ( Fig. 3B ; Supplementary 
(D) The cell number ratio of tumor infiltrating T cells derived from Cd69
-/-BM against those from Cd69 +/+ BM in the mixed BM chimera mice. The ratio was corrected with the cell number ratio in the spleen (n = 6). Data are representative of at least two independent experiments. One sample two-sided Student's t-test. For all panels, *P < 0.05; **P < 0.01; ****P < 0.0001. Figure S3C ), whereas the frequencies of IFNγ-producing and IFNγ/TNFα-double-producing cells among CD4 + T cells in Cd69 -/-and Cd69 +/+ mice were comparable (Supplementary Figure S3D) . These data show that CD69 deficiency controls not only the numbers of TILs but also the effector functions of tumor-infiltrating CD8 + T cells.
CD69-deficient tumor-infiltrating CD8T cells showed less exhaustion
Why are the effector functions of CD69-deficient tumor-infiltrating T cells enhanced? Given that the exhaustion of TILs is reportedly one of the major reasons underlying weakened anti-tumor immunity, which results in tumor progression (20), we next examined the relationship between the expression of CD69 and T-cell exhaustion. We used PD-1 and Tim3 as markers to identify the status of tumor-infiltrating CD8 + T cells and considered PD-1 + cells as 'extremely exhausted T cells' (24, 25) (Fig. 4A) . Importantly, the percentage of CD69 + cells was high in the weakly exhausted PD-1 hi
Tim3
-cells and even higher in the extremely exhausted PD-1 hi
+ cells, indicating a strong relationship between the expression of CD69 and exhaustion (Fig. 4A) +/+ mice at 3 and 5 weeks after tumor inoculation (Fig. 4B) . These data suggest that the CD69 expression on tumor-infiltrating CD8 + T cells may contribute to the induction of CD8 + T-cell exhaustion. We next examined whether or not the attenuated exhaustion of CD69-deficient tumor-infiltrating CD8 + T cells was caused by a cell-intrinsic mechanism. We injected an equal number of CD90.1 Cd69 +/+ and CD90.2 Cd69 -/-T cells into nu/nu host mice, inoculated 4T1-luc2 tumor cells the next day and analyzed the TILs 3 weeks later (Fig. 4C) . The percentages of both PD-1 hi
-weakly exhausted CD8 + T cells and PD-1 hi
+ extremely exhausted CD8 + T cells were of Cd69 +/+ and Cd69 -/-mice. Cells were stimulated with PMA and ionomycin in a monensin-containing medium for 4 h before staining (at least n = 6). Data are representative of at least three independent experiments. Unpaired two-sided Student's t-test. For all panels, *P < 0.05. For all panels, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. significantly lower in cells from Cd69 -/-mice than in cells from Cd69 +/+ mice, while there was no significant change in the percentage of PD-1 lo
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Tim3
-CD8 + T cells within the same host mice (Fig. 4D) . These results indicate that an absence of CD69 expression by CD8 + T cells contributes to the prevention of T-cell exhaustion.
Anti-CD69 antibody treatment prevented tumor progression
Finally, we examined whether or not anti-CD69 antibody treatment had any influence on tumor progression. We injected anti-CD69 antibodies into host mice twice a week from day 0 (when the mice were inoculated with 4T1-luc2 tumor cells) and the numbers of TILs and lung metastasis were analyzed 3 and 5 weeks later (Supplementary Figure S4A) . We found that anti-CD69 antibody treatment resulted in a significant reduction of tumor growth (Supplementary Figure S4B) Figure S4C and S4D ) and a significant decrease in the incidence of lung metastasis (Supplementary Figure S4E) . We further examined the effects of anti-CD69 antibody treatment on established 4T1-luc2 tumors that had been injected with anti-CD69 antibodies 2 weeks after 4T1-luc2 cell inoculation (Fig. 5A) . We found that anti-CD69 antibody treatment resulted in a significant increase in the numbers of CD4 + and CD8 + tumor-infiltrating T cells, while the frequency of PD1 hi
Tim3
+ exhausted CD8 + T cells was reduced ( Fig. 5B  and 5C ). Furthermore, significant attenuation of lung metastasis was observed (Fig. 5D ). These findings suggest that anti-CD69 antibody treatment prevented tumor progression by inhibiting T-cell exhaustion and increasing the number of tumor-infiltrating T cells. 
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Discussion
We identified a novel role of CD69 in anti-tumor immunity, wherein CD69 regulates the exhaustion of tumor-infiltrating T cells and weakens the anti-tumor immune responses. Mice lacking CD69 showed attenuated tumor growth and lung metastasis with an increased number of IFNγ-producing tumor-infiltrating T cells and reduced CD8 + T-cell exhaustion. Furthermore, the treatment of tumor-bearing mice with anti-CD69 monoclonal antibodies significantly attenuated the exhaustion of tumor-infiltrating T cells and enhanced the protection against metastasis, suggesting the efficacy of anti-CD69 antibodies in the treatment of malignant tumors.
How does CD69 negatively affect anti-tumor immunity? CD69 is known to be expressed on all activated leukocytes; thus, any activated cell may be affected by CD69 deficiency. Indeed, previous studies have reported that Cd69 -/-mice show enhanced NK-mediated anti-tumor responses against MHC class I-deficient tumors (i.e. RMA-S and RM-1) (17, 19) . However, in our current study, we noted no marked differences in the number of NK cells in Cd69 -/-mice with 4T1-luc2 tumors and found that the CD69 expression on T cells is crucial for weakening the anti-tumor immune response. Although the cells mainly targeted by CD69 deficiency for the enhancement of anti-tumor immunity may differ depending on the experimental conditions, it is important to understand that CD69 works negatively against anti-tumor immunity, and that CD69 deficiency enhances the anti-tumor immune response and prevents tumor growth and metastasis.
One of the important findings of this study is that CD69 deficiency attenuated the exhaustion of tumor-infiltrating T cells and enhanced anti-tumor immunity, thereby resulting in the prevention of tumor progression. However, how CD69 mediates T-cell exhaustion within the tumor remains unclear. It has been suggested that continuous tumor antigen stimulation in T cells within the tumor microenvironment is a major cause of T-cell exhaustion (26, 27) . Given that CD69 has been reported to regulate cell retention (2), one possible mechanism of CD69-mediated cell exhaustion is that CD69 molecules expressed on tumor-infiltrating T cells may react with unknown ligands in the tumor, through which CD69 + tumor-infiltrating T cells are retained within the tumor, and thereby received continuous tumor antigen stimulation, resulting in T-cell exhaustion with the increased expression of PD1 and Tim3. Indeed, we found that tumor-infiltrating T cells, especially PD1 hi Tim3 + -exhausted T cells, express high levels of CD69, suggesting a role for CD69 in these cells. Further studies will be needed to test this possibility. One way that this might be accomplished is by exploring putative CD69 ligands within the tumor. Alternatively, CD69-mediated signaling may contribute to T-cell exhaustion. The CD69 cytosolic tail contains eight serine residues and one (mouse) or two (human) threonine residues; thus, the potential for CD69 signaling exists (2) . This fact raised the possibility that CD69-mediated signaling in tumor-infiltrating cells might enhance the induction of T-cell exhaustion.
Since the emergence of checkpoint inhibition therapy, immunotherapy targeting T-cell exhaustion has become a new alternative for tumor pharmacotherapy (28) . While the usage of immune checkpoint inhibitors, such as PD-1, PD-L1 and CTLA4 antibodies, is becoming widespread, there are growing concerns about the potential risk of autoimmunity and potential fatal adverse events (29) (30) (31) . We think that CD69 blockade attenuates T-cell exhaustion without the abnormal activation of undesirous T cells, which would be at an advantage compared to the 'classical' checkpoint inhibitors that remove the 'immunological brakes', thereby resulting in the activation of various T cells including autoreactive T cells. We previously showed that CD69 plays an important role in the pathogenesis of inflammatory diseases in various tissues, regardless of the types of inflammation, and that its blockade ameliorates inflammatory responses (10, 11, 13, 32) , while checkpoint blockade exacerbates inflammatory diseases (33) . We, therefore, think that anti-CD69 antibody therapy may be a new therapy for patients for whom there have been no effective or satisfactory treatments.
In conclusion, we showed that CD69 plays a novel and crucial role in anti-tumor immunity by regulating the exhaustion of T cells. We think that this finding will lead to a deeper understanding of the mechanisms underlying T-cell exhaustion and tumor immune escape. CD69 may be an attractive target for cancer immunotherapy not only for its effectiveness but also for its potency in providing treatment with reduced side effects and restrictions.
